Vaxcyte, Inc. Common Stock
Veridion Score
Composite trend over time
Why is PCVX moving today?
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for PCVX.
PCVX insider activity
Vaxcyte, Inc. Common Stock
3 insiders bought in the last 90 days
Net selling: -$7.0M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-26 | 2026-06-26 | PICKERING GRANT | Insider | sell | $56.27 | 191 | 134,215 | $11K | SEC Form 4 |
| 2026-06-26 | 2026-06-26 | PICKERING GRANT | Insider | sell | $55.30 | 602 | 134,406 | $33K | SEC Form 4 |
| 2026-06-26 | 2026-06-26 | PICKERING GRANT | Insider | sell | $54.22 | 207 | 135,008 | $11K | SEC Form 4 |
| 2026-06-26 | 2026-06-26 | PICKERING GRANT | Insider | sell | $55.99 | 332 | 134,215 | $19K | SEC Form 4 |
| 2026-06-26 | 2026-06-26 | PICKERING GRANT | Insider | sell | $55.23 | 356 | 134,547 | $20K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 64 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moPCVX contract awards, year to date.
Public federal awards linked to this ticker.
PCVX lobbying filings, year to date.
Registered lobbying filings matched to Vaxcyte, Inc. Common Stock.